Applications are now closed for the Spex Capital – Medcity Investment Call

Spex Capital and London’s life sciences cluster organisation MedCity launched their joint call at the close of 2021, as part of their exclusive partnership to identify and fund the next generation of digital health and medtech innovators.

Following a thorough review of over 200 applicants under the scrutiny of two independent panels, we have now shortlisted 35 companies to progress to the next stage, involving in-person interviews with our Teams, Advisory Boards and other industry leaders.

We would like to take this opportunity to thank all the outstanding applicants across the call.

If you have any questions, please send queries to: spexcapital@medcityhq.com

Applications are now closed for the Spex Capital – Medcity Investment Call

Spex Capital and London’s life sciences cluster organisation MedCity launched their joint call at the close of 2021, as part of their exclusive partnership to identify and fund the next generation of digital health and medtech innovators.

Following a thorough review of over 200 applicants under the scrutiny of two independent panels, we have now shortlisted 35 companies to progress to the next stage, involving in-person interviews with our Teams, Advisory Boards and other industry leaders.

We would like to take this opportunity to thank all the outstanding applicants across the call.

If you have any questions, please send queries to: spexcapital@medcityhq.com

Applications are now closed

Applications are now closed

Our Investment call

Spex Capital has partnered with MedCity to source, evaluate and fund early-stage health tech ventures and accelerate their route to commercialisation. This exclusive partnership will support several calls for innovative companies seeking investment over the next two years.

The call is targeted at innovative health tech companies seeking Seed or Series A investment. Under the joint call, MedCity will use its extensive networks and expertise to attract and assess applications from investment-ready companies developing breakthrough digital health tech and medtech. Spex Capital will look to invest up to a max of £5 million per target company. The average ticket is expected to between £500k and £2 million but smaller tickets will be welcome. Successful applicants will also benefit from access to advisory teams with deep sector experience and from our special ongoing relationship with the NHS England.

Our Investment call

Spex Capital has partnered with MedCity to source, evaluate and fund early-stage health tech ventures and accelerate their route to commercialisation. This exclusive partnership will support several calls for innovative companies seeking investment over the next two years.

The call is targeted at innovative health tech companies seeking Seed or Series A investment. Under the joint call, MedCity will use its extensive networks and expertise to attract and assess applications from investment-ready companies developing breakthrough digital health tech and medtech. Spex Capital will look to invest up to a max of £5 million per target company. The average ticket is expected to between £500k and £2 million but smaller tickets will be welcome. Successful applicants will also benefit from access to advisory teams with deep sector experience and from our special ongoing relationship with the NHS England.

About Medcity

MedCity represents the life sciences cluster for London. MedCity boosts innovation and investment in the region to secure the UK’s position as a global science superpower. Working in close partnership with London’s world-leading universities, MedCity connects private industry with partners in the NHS, charity sector and research institutes to catalyse exciting new opportunities that advance cutting-edge R&D in areas such as AI, diagnostics, and advanced therapies.

MedCity builds collaborations to accelerate uptake of medical innovation and growth across the UK. We help policymakers understand what life sciences requires to thrive in a competitive international landscape. MedCity contributes to the development of industry standards, including the NICE Evidence Standards Framework for Digital Health.

About Medcity

MedCity represents the life sciences cluster for London. MedCity boosts innovation and investment in the region to secure the UK’s position as a global science superpower. Working in close partnership with London’s world-leading universities, MedCity connects private industry with partners in the NHS, charity sector and research institutes to catalyse exciting new opportunities that advance cutting-edge R&D in areas such as AI, diagnostics, and advanced therapies.

MedCity builds collaborations to accelerate uptake of medical innovation and growth across the UK. We help policymakers understand what life sciences requires to thrive in a competitive international landscape. MedCity contributes to the development of industry standards, including the NICE Evidence Standards Framework for Digital Health.